ArticleIntensive care medicine2026
Impact of a strategy using multiplex PCR on targeted antibiotic therapy for patients with suspected ventilator-associated pneumonia or hospital-acquired pneumonia requiring mechanical ventilation: a randomized, single-blind trial.
Article in Intensive care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVentilator-associated pneumonia (VAP) and hospital-acquired pneumonia requiring mechanical ventilation (vHAP) are frequent in intensive care units and require prompt diagnosis. The FilmArray Pneumonia Panel (FAPP) enables fast pathogen identification, but its clinical impact remains uncertain.
objectiveTo assess whether adding FAPP to conventional microbiology increases the rate of targeted antimicrobial therapy (AMT) in patients with suspected VAP or vHAP.
methodOpen-label, multicenter randomized-controlled trial in immunocompetent adults with suspected VAP or vHAP. Patients were randomized to management with FAPP plus conventional microbiology or conventional microbiology alone. The primary outcome was the proportion of patients receiving targeted AMT 24 h after inclusion.
resultsFrom June 2020 to September 2023, 156 patients were randomized; 146 were analyzed (74 intervention, 72 control), as 10 did not provide consent for continued participation. Median age was 58 years (interquartile range, 43-70), 67.8% were male, 84.9% had VAP, and mean SOFA score was 8.0 ± 3.5. Targeted AMT at 24 h was achieved in 35.1% of the experimental group versus 23.6% of the control group [absolute difference (AD), 11.5%; 95% confidence interval (CI), -0.03 to 26.2, p = 0.13]. Secondary outcomes did not differ significantly. Among patients with culture-documented pneumonia (45.9%), targeted AMT at 24 h was achieved in 55.3% versus 31.0%, respectively (AD, 24.2%; 95% CI, 1.1 to 47.4, p = 0.048).
conclusionAdding FAPP was not associated with a significant increase in targeted AMT at 24 h in patients with suspected VAP or vHAP, except in those with confirmed pneumonia.
Indexed as
Identifiers
42622675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.